The testosterone replacement therapy (TRT) market is expected to grow rapidly around the world despite serious cardiovascluar risks associated with the hormone treatment, according to Transparency Market Research, a firm that provides current market trends and forecasts.
Testosterone treatments are designed to boost levels of the hormone testosterone in men who have low testosterone due to injury or disease, a condition known as hypogonadism. It is not intended for men with naturally occurring age-related hypogonadism.
The treatment has “gained momentum in the last decade,” according to the market research firm, primarly in the United States thanks to aggressive direct-to-consumer advertising by manufacturers of testosterone products. In many cases, men are not tested to determine if they have “Low T” before they are prescribed the treatment.
Recent studies have linked testosterone therapy to a 30 percent increased risk of heart attacks, strokes or death after three years of use. Another study found that men had a significant increased risk of heart attack or stroke in the first three months of use.
Concerned about testosterone side effects and the overprescribing of the hormone, the Food and Drug Administration (FDA) has ordered new warnings be placed on the safety labels of all testosterone products, and placed tighter prescribing instructions to curb overprescribing.
Nonetheless, Transparency Market Research says, “There is a large opportunity for TRT market in Asia-Pacific with more than 81 million of combined population in India and China above the age of 65.”
Manufacturers of testosterone products – which include Endo Pharmaceuticals, Abbott Laboratories, Columbia Laboratories, Auxilium Pharmaceuticals, Eli Lily and Company, GlaxoSmithKline, Bayer Schering Pharma, and Watson Pharmaceuticals – are expected to engage in strong promotional activities “to educate patients and physicians,” the firm said.